HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes

SHENZHEN, CHINA and ROCKVILLE, MD, October 1, 2020 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patientswith non-alcoholic steatohepatitis (NASH) and other chronic liver dis

Chardan Capital Markets will host a Leadership Call with HighTide Therapeutics. The call will be moderated by Michael Morabito, PhD, Senior Research Analyst.